XE kit gets CE mark
The MassTrak immunosuppressants XE kit from Waters has obtained its CE mark in accordance with the IVD Directive 98/79/EC.
The MassTrak immunosuppressants XE kit from Waters has obtained its CE mark in accordance with the IVD Directive 98/79/EC. When used with the company’s LC–MS–MS system, the kit provides quantitative measurement of the immunosuppressive drugs tacrolimus in liver and kidney transplant patients and everolimus in adult kidney and cardiac transplant patients from human whole blood samples.
"LC–MS plays an increasingly important role in many clinical laboratories today. Waters is committed to advancing technology-based diagnostic solutions in the clinical laboratory that impact the quality of results in many areas including immunosuppressant drug monitoring", said Mark Bruns, senior director, Clinical Business Operations, Waters Division.
The company reports that with the instrumentation and kit, clinical laboratories in the European Economic Area and Switzerland will no longer have to spend time and money to develop and validate in house LC–MS–MS methods for tacrolimus or everolimus, or source calibrators, QCs and internal standards.
The company’s clinical specialists will support the system and methodology. The instrumentation and kit is currently only available for sale in the European Economic Area and Switzerland.
For more information on the products visit www.waters.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
